NCT04044937CompletedPhase 2
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 143 (actual)
- First submitted
- 25 Jul 2019
- Start date
- 29 Oct 2018
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- Thomas Hope
- Diseases
- Glioblastoma, Childhood cancers
- NCT number
- NCT04044937
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 143
- From 29 Oct 2018 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient with known incompatibility to PET or computed tomography (CT)/MRI scans.
- Patient unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation.
- Sedation or anesthesia can be used for patients who cannot tolerate the exam.
Who the study is looking for
- Age \> 3 years.
- Presence or suspicion of intracranial neoplasm in two populations.
- Population 1: Patients after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on magnetic resonance imaging (MRI). Three sub-populations will be considered:
- Recurrent metastatic lesions.
- Recurrent high-grade gliomas (grades 3 and 4).
- Recurrent low-grade gliomas (grades 1 and 2).
- Population 2: Patients prior to primary treatment with planned biopsy or surgical resection.
Age in the registry: 3 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.